BMS-986322 + rosuvastatin

BMS-986322 + rosuvastatin is an investigational combination of lomedeucitinib (BMS-986322), a second-generation selective oral TYK2 (Tyrosine Kinase 2) inhibitor, with rosuvastatin, a widely prescribed statin that inhibits HMG-CoA reductase for lipid lowering. BMS-986322 (lomedeucitinib) was developed for immune-mediated conditions such as moderate-to-severe psoriasis, targeting TYK2 to block intracellular signaling of cytokines implicated in autoimmune and inflammatory diseases. Rosuvastatin is a small-molecule lipid-lowering agent used primarily to reduce LDL cholesterol and prevent cardiovascular disease. The rationale for the combination in clinical research is to study pharmacokinetic interactions or potential safety signals, as suggested by early-phase clinical trials in healthy participants assessing drug-drug interactions (and not necessarily for a therapeutic intent combining both mechanisms). The combination is not an approved or marketed therapy, and BMS-986322's development was deprioritized after Phase 2 as Bristol Myers Squibb focused on other TYK2 inhibitors in its portfolio.

Other names

lomedeucitinib + rosuvastatin